PLTP activity is a risk factor for subsequent cardiovascular events in CAD patients under statin therapy: the AtheroGene study
Standard
PLTP activity is a risk factor for subsequent cardiovascular events in CAD patients under statin therapy: the AtheroGene study. / Schlitt, Axel; Blankenberg, Stefan; Bickel, Christoph; Lackner, Karl J; Heine, Gunnar H; Buerke, Michael; Werdan, Karl; Maegdefessel, Lars; Raaz, Uwe; Rupprecht, Hans J; Munzel, Thomas; Jiang, Xian-Cheng.
in: J LIPID RES, Jahrgang 50, Nr. 4, 04.2009, S. 723-729.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - PLTP activity is a risk factor for subsequent cardiovascular events in CAD patients under statin therapy: the AtheroGene study
AU - Schlitt, Axel
AU - Blankenberg, Stefan
AU - Bickel, Christoph
AU - Lackner, Karl J
AU - Heine, Gunnar H
AU - Buerke, Michael
AU - Werdan, Karl
AU - Maegdefessel, Lars
AU - Raaz, Uwe
AU - Rupprecht, Hans J
AU - Munzel, Thomas
AU - Jiang, Xian-Cheng
PY - 2009/4
Y1 - 2009/4
N2 - Phospholipid transferprotein (PLTP) mediates both net transfer and exchange of phospholipids between different lipoproteins. Although many studies have investigated the role of PLTP in atherogenesis, the role of PLTP in atherosclerotic diseases is unclear. We investigated the association of serum PLTP activity with the incidence of a combined endpoint (myocardial infarction and cardiovascular death) and its relation to other markers of atherosclerosis in 1,085 patients with angiographically documented coronary artery disease (CAD). In the median follow-up of 5.1 years, 156 patients had suffered from the combined endpoint of myocardial infarction or cardiovascular death including 47 of 395 patients who were on statins at baseline. In Kaplan-Meyer analyses serum PLTP activity was not associated with the combined endpoint in all patients. However, in the subgroup of patients receiving statins at baseline, PLTP was shown to be a significant predictor of cardiovascular outcome (P = 0.019), and this also remained stable in univariate (P = 0.027) and multivariate cox regression analyses (P = 0.041) including potential confounders (classical risk factors, HDL cholesterol (HDL-C), and others). We showed in our study that, under statin treatment, high plasma PLTP activity was related to fatal and nonfatal cardiovascular events in CAD patients.
AB - Phospholipid transferprotein (PLTP) mediates both net transfer and exchange of phospholipids between different lipoproteins. Although many studies have investigated the role of PLTP in atherogenesis, the role of PLTP in atherosclerotic diseases is unclear. We investigated the association of serum PLTP activity with the incidence of a combined endpoint (myocardial infarction and cardiovascular death) and its relation to other markers of atherosclerosis in 1,085 patients with angiographically documented coronary artery disease (CAD). In the median follow-up of 5.1 years, 156 patients had suffered from the combined endpoint of myocardial infarction or cardiovascular death including 47 of 395 patients who were on statins at baseline. In Kaplan-Meyer analyses serum PLTP activity was not associated with the combined endpoint in all patients. However, in the subgroup of patients receiving statins at baseline, PLTP was shown to be a significant predictor of cardiovascular outcome (P = 0.019), and this also remained stable in univariate (P = 0.027) and multivariate cox regression analyses (P = 0.041) including potential confounders (classical risk factors, HDL cholesterol (HDL-C), and others). We showed in our study that, under statin treatment, high plasma PLTP activity was related to fatal and nonfatal cardiovascular events in CAD patients.
KW - Aged
KW - Atherosclerosis/blood
KW - Case-Control Studies
KW - Coronary Artery Disease/blood
KW - Female
KW - Follow-Up Studies
KW - Humans
KW - Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
KW - Kaplan-Meier Estimate
KW - Male
KW - Middle Aged
KW - Myocardial Infarction/blood
KW - Phospholipid Transfer Proteins/blood
KW - Prognosis
KW - Risk Factors
U2 - 10.1194/jlr.M800414-JLR200
DO - 10.1194/jlr.M800414-JLR200
M3 - SCORING: Journal article
C2 - 19001358
VL - 50
SP - 723
EP - 729
JO - J LIPID RES
JF - J LIPID RES
SN - 0022-2275
IS - 4
ER -